Despite Granting a Request for Rehearing, the PTAB Maintained Its Finding that Teva’s Copaxone Claims Were Unpatentable as Obvious, PTAB Litigation Blog
Visit the Jones Day PTAB Litigation Blog.
In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC v. Yeda Research & Development Co. Ltd., IPR2015-00643; -00644; -00830, the PTAB granted-in-part Patent Owner Teva’s request for rehearing of the Final Written Decisions finding every claim of the challenged patents obvious over the prior art. In granting rehearing in part, the PTAB vacated its original decisions and concurrently entered modified Final Written Decisions maintaining that the challenged claims are unpatentable as obvious over the prior art.
